New cocktail of 4 drugs shows promise for Hard-to-Treat myeloma
NCT ID NCT07150104
First seen Sep 30, 2025 · Last updated May 13, 2026 · Updated 31 times
Summary
This study tests a combination of four drugs (belantamab mafodotin, nirogacestat, pomalidomide, and dexamethasone) in people with multiple myeloma that has come back or not responded to at least three prior treatments. The goal is to find the safest dose and see how well the combination shrinks tumors. The trial is for adults aged 18 and older and is currently not recruiting new participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Salvador, Estado de Bahia, 41253-190, Brazil
-
GSK Investigational Site
Porto Alegre, Rio Grande do Sul, 90110-270, Brazil
-
GSK Investigational Site
Halifax, Nova Scotia, B3H 1V7, Canada
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Mexico City, 01330, Mexico
-
GSK Investigational Site
Oslo, 0450, Norway
-
GSK Investigational Site
Lublin, 20-081, Poland
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Ulsan, 44033, South Korea
-
GSK Investigational Site
Falun, SE-791 82, Sweden
Conditions
Explore the condition pages connected to this study.